专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5679703A Tricyclic compounds having ACAT inhibiting activity 失效
标题翻译：具有ACAT抑制活性的三环化合物
公开(公告)号：US5679703A
公开(公告)日：1997-10-21
申请号：US523843
申请日：1995-09-07
申请人： Masashi Yanase , Toshiaki Kumazawa , Shiro Shirakura , Eiko Oishi , Koji Yamada
发明人： Masashi Yanase , Toshiaki Kumazawa , Shiro Shirakura , Eiko Oishi , Koji Yamada
IPC分类号： C07C275/28 , C07D313/12 , A61K31/335 , A61K31/38 , C07D337/12
CPC分类号： C07C275/28 , C07D313/12 , C07C2103/32
摘要： Disclosed is a tricyclic compound represented by formula (I): ##STR1## where X.sup.1 -X.sup.2 represents CH.dbd.CH--CH.dbd.CH, CH.dbd.CH--CH.dbd.N or S--CH.dbd.CH; Y--Z represents CH.sub.2 --O or CH.sub.2 --S; then L--M represents C.dbd.CR.sup.9 (in which R.sup.9 represents hydrogen or lower alkyl) or CH--CR.sup.10 R.sup.11 (in which each of R.sup.10 and R.sup.11 independently represents hydrogen or lower alkyl); W represents NR.sup.4 (in which R.sup.4 represents hydrogen or lower alkyl) or O; each of R.sup.1, R.sup.2 and R.sup.3 independently represents hydrogen, lower alkyl, lower alkoxy, halogen, nitro, amino or mono or di-lower alkyl-substituted amino; R.sup.5 represents hydrogen or lower alkyl; each of R.sup.6, R.sup.7 and R.sup.8 independently represents hydrogen, halogen, lower alkyl or lower alkoxy; provided that when Y--Z represents CH.dbd.CH or CH.sub.2 CH.sub.2, then L--M represents C.dbd.CR.sup.9 (in which R.sup.9 has the same meaning as defined above),or CH--CR.sup.10a R.sup.11a (in which each of R.sup.10a and R.sup.11a represents lower alkyl of R.sup.10 and R.sup.11); and a pharmaceutically acceptable salt thereto. The compound and its salt have an ACAT inhibiting activity and are expected to have preventive and therapeutic effects on hyperlipemia and arteriosclerosis.
摘要翻译：公开了由式（I）表示的三环化合物：其中X 1 -X 2表示CH = CH-CH = CH，CH = CH-CH = N或S-CH = CH; Y-Z表示CH 2 -O或CH 2 -S; 那么L-M表示C = CR9（其中R9表示氢或低级烷基）或CH-CR10R11（其中R10和R11各自独立地表示氢或低级烷基）; W表示NR4（其中R4表示氢或低级烷基）或O; R 1，R 2和R 3各自独立地表示氢，低级烷基，低级烷氧基，卤素，硝基，氨基或单或二低级烷基取代的氨基; R5代表氢或低级烷基; R 6，R 7和R 8各自独立地表示氢，卤素，低级烷基或低级烷氧基; 条件是当YZ表示CH = CH或CH 2 CH 2时，LM表示C = CR 9（其中R9具有与上述相同的含义）或CH-CR10aR11a（其中R10a和R11a各自表示R10和R11的低级烷基） ; 和其药学上可接受的盐。该化合物及其盐具有ACAT抑制活性，预期对高脂血症和动脉硬化具有预防和治疗作用。

2. 发明授权

US5340807A Tricyclic compounds and intermediates thereof 失效
标题翻译：三环化合物及其中间体
公开(公告)号：US5340807A
公开(公告)日：1994-08-23
申请号：US989906
申请日：1992-12-11
申请人： Toshiaki Kumazawa , Masashi Yanase , Hiroyuki Harakawa , Hiroyuki Obase , Shoji Oda , Shiro Shirakura , Koji Yamada , Kazuhiro Kubo
发明人： Toshiaki Kumazawa , Masashi Yanase , Hiroyuki Harakawa , Hiroyuki Obase , Shoji Oda , Shiro Shirakura , Koji Yamada , Kazuhiro Kubo
IPC分类号： A61K31/335 , A61K31/165 , A61K31/18 , A61K31/19 , A61K31/215 , A61K31/235 , A61K31/275 , A61K31/38 , A61K31/435 , A61K31/44 , A61K31/55 , A61P3/06 , A61P9/10 , A61P43/00 , C07C233/65 , C07C235/46 , C07C235/48 , C07C237/40 , C07C323/40 , C07C323/62 , C07C327/26 , C07C331/08 , C07D221/16 , C07D223/20 , C07D233/58 , C07D313/12 , C07D337/12 , C07D471/04 , C07D491/04 , C07D491/044 , C07D495/04 , A01N43/46 , C07D273/02 , C07D313/06
CPC分类号： C07D491/04 , C07C233/65 , C07D223/20 , C07D313/12 , C07D337/12 , C07C2103/32 , Y10S514/824
摘要： Disclosed is a tricyclic compound represented by the formula (I): ##STR1## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represents hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, amino, C1-6 alkylamino, halogenated C1-6 alkyl, halogenated C1-6 alkoxy, halogen, nitro, cyano, carboxy, C1-6 alkoxycarbonyl, hydroxymethyl, CR.sup.9 R.sup.10 CO.sub.2 R.sup.11 (wherein each of R.sup.9, R.sup.10 and R.sup.11 independently represents hydrogen or C1-6 alkyl) or CONR.sup.12 R.sup.13 (wherein each of R.sup.12 and R.sup.13 independently represents hydrogen or C1-6 alkyl); R.sup.5 represents hydrogen or C1-6 alkyl; each of R.sup.6, R.sup.7 and R.sup.8 independently represents hydrogen, C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkanoyloxy, C1-6 alkylthio, thiocyanato or halogen; X represents CH or N; Y.sup.1 -Y.sup.2 represents CH.sub.2 --O, CH.sub.2 --(O).sub.n, (wherein n represents 0, 1, or 2), CH.sub.2 CH.sub.2, CH.dbd.CH or CON(R.sup.14) (wherein R.sup.14 represents hydrogen or C1-6 alkyl) and Z represents oxygen or sulfur, or a pharmaceutically acceptable salt thereof. The compound possesses an acyl coenzyme A: cholesterol acyltransferase-inhibiting activity, and thus are expected to have preventive and therapeutic effects on hyperlipemia and arteriosclerosis.
摘要翻译：公开了由式（I）表示的三环化合物：其中R 1，R 2，R 3和R 4各自独立地表示氢，C 1-6烷基，C 1-6烷氧基，C 1-6烷硫基，氨基， C 1-6烷基氨基，卤代C 1-6烷基，卤代C 1-6烷氧基，卤素，硝基，氰基，羧基，C 1-6烷氧基羰基，羟甲基，CR 9 R 10 CO 2 R 11（其中R 9，R 10和R 11各自独立地表示氢或C 1-6烷基）或CONR 12 R 13（其中R 12和R 13各自独立地表示氢或C 1-6烷基）; R5表示氢或C1-6烷基; R 6，R 7和R 8各自独立地表示氢，C 1-6烷基，羟基，C 1-6烷氧基，C 1-6烷酰氧基，C 1-6烷硫基，氰硫基或卤素; X表示CH或N; Y1-Y2表示CH2-O，CH2-（O）n，（其中n表示0,1或2），CH2CH2，CH = CH或CON（R14）（其中R14表示氢或C1-6烷基）和Z 表示氧或硫，或其药学上可接受的盐。该化合物具有酰基辅酶A：胆固醇酰基转移酶抑制活性，因此预期对高脂血症和动脉硬化具有预防和治疗作用。

3. 发明授权

US5478835A Tricyclic compounds and intermediates thereof 失效
标题翻译：三环化合物及其中间体
公开(公告)号：US5478835A
公开(公告)日：1995-12-26
申请号：US236097
申请日：1994-05-02
申请人： Toshiaki Kumazawa , Masashi Yanase , Hiroyuki Harakawa , Hiroyuki Obase , Shoji Oda , Shiro Shirakura , Koji Yamada , Kazuhiro Kubo
发明人： Toshiaki Kumazawa , Masashi Yanase , Hiroyuki Harakawa , Hiroyuki Obase , Shoji Oda , Shiro Shirakura , Koji Yamada , Kazuhiro Kubo
IPC分类号： A61K31/335 , A61K31/165 , A61K31/18 , A61K31/19 , A61K31/215 , A61K31/235 , A61K31/275 , A61K31/38 , A61K31/435 , A61K31/44 , A61K31/55 , A61P3/06 , A61P9/10 , A61P43/00 , C07C233/65 , C07C235/46 , C07C235/48 , C07C237/40 , C07C323/40 , C07C323/62 , C07C327/26 , C07C331/08 , C07D221/16 , C07D223/20 , C07D233/58 , C07D313/12 , C07D337/12 , C07D471/04 , C07D491/04 , C07D491/044 , C07D495/04 , C07C207/00 , C07C237/00
CPC分类号： C07D491/04 , C07C233/65 , C07D223/20 , C07D313/12 , C07D337/12 , C07C2103/32 , Y10S514/824
摘要： Disclosed is a tricyclic compound represented by the formula (I): ##STR1## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represents hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, amino, C1-6 alkylamino, halogenated C1-6 alkyl, halogenated C1-6 alkoxy, halogen, nitro, cyano, carboxy, C1-6 alkoxycarbonyl, hydroxymethyl, CR.sup.9 R.sup.10 CO.sub.2 R.sup.11 (wherein each of R.sup.9, R.sup.10 and R.sup.11 independently represents hydrogen or C1-6 alkyl) or CONR.sup.12 R.sup.13 (wherein each of R.sup.12 and R.sup.13 independently represents hydrogen or C1-6-alkyl); R.sup.5 represents hydrogen or C1-6 alkyl; each of R.sup.6, R.sup.7 and R.sup.8 independently represents hydrogen, C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkanoyloxy, C1-6 alkylthio, thiocyanato or halogen; X represents CH or N; Y.sup.1 -Y.sup.2 represents CH.sub.2 -O, CH.sub.2 -S(O).sub.n, (wherein n represents 0, 1, or 2), CH.sub.2 CH.sub.2, CH.dbd.CH or CON(R.sup.14) (wherein R.sup.14 represents hydrogen or C1-6 alkyl) and Z represents oxygen or sulfur, or a pharmaceutically acceptable salt thereof. The compound possesses an acyl coenzyme A: cholesterol acyltransferase-inhibiting activity, and thus are expected to have preventive and therapeutic effects on hyperlipemia and arteriosclerosis.
摘要翻译：公开了由式（I）表示的三环化合物：其中R 1，R 2，R 3和R 4各自独立地表示氢，C 1-6烷基，C 1-6烷氧基，C 1-6烷硫基，氨基， C 1-6烷基氨基，卤代C 1-6烷基，卤代C 1-6烷氧基，卤素，硝基，氰基，羧基，C 1-6烷氧基羰基，羟甲基，CR 9 R 10 CO 2 R 11（其中R 9，R 10和R 11各自独立地表示氢或C 1-6烷基）或CONR 12 R 13（其中R 12和R 13各自独立地表示氢或C 1-6 - 烷基）; R5表示氢或C1-6烷基; R 6，R 7和R 8各自独立地表示氢，C 1-6烷基，羟基，C 1-6烷氧基，C 1-6烷酰氧基，C 1-6烷硫基，氰硫基或卤素; X表示CH或N; Y1-Y2表示CH2-O，CH2-S（O）n，（其中n表示0,1或2），CH2CH2，CH = CH或CON（R14）（其中R14表示氢或C1-6烷基） Z表示氧或硫，或其药学上可接受的盐。该化合物具有酰基辅酶A：胆固醇酰基转移酶抑制活性，因此预期对高脂血症和动脉硬化具有预防和治疗作用。

4. 发明申请

US20070185168A1 Piperidine derivatives 审中-公开
标题翻译：哌啶衍生物
公开(公告)号：US20070185168A1
公开(公告)日：2007-08-09
申请号：US11547810
申请日：2005-04-07
申请人： Haruki Takai , Shunji Kunori , Shiro Shirakura , Katsumi Shinoda , Atsuko Mizutani , Koji Yamada , Shinichiro Toki , Tomoyuki Nishikawa
发明人： Haruki Takai , Shunji Kunori , Shiro Shirakura , Katsumi Shinoda , Atsuko Mizutani , Koji Yamada , Shinichiro Toki , Tomoyuki Nishikawa
IPC分类号： A61K31/4439
CPC分类号： C07D409/14
摘要： For example, a piperidine derivative represented by following formula (I) (wherein, —C(═O)-Z- represents —C(═O)—CH2—, —C(═O)—C(CH3)2—, —C(═O)—NH—, —C(═O)—O—, —C(═O)—S—, —C(═O)—CH2CH2—, —C(═O)—CH═CH—, —C(═O)—CH2O—, —C(═O)—CH2S—, —C(═O)—CH2CH2CH2— or —C(═O)—NR8CH2—; R1 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like; R2 represents a hydrogen atom or hydroxy; R3 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like; R5 represents a hydrogen atom, hydroxy, or the like; R6 represents a hydrogen atom, hydroxy, substituted or unsubstituted lower alkyl, or the like, etc.; R7 represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like; n and k each independently represents an integer of 0 to 2; and ---- represents a single bond, or a double bond together with R4, where in case ---- is a single bond, R4 represents a hydrogen atom, hydroxy, or the like) or a pharmaceutically acceptable salt thereof and the like having an antagonistic activity for a glutamic acid receptor (NR2B/NMDA receptor) of an N-methyl-D-aspartic acid (NMDA) type containing an NR2B subunit are provided.
摘要翻译：例如，由下式（I）表示的哌啶衍生物（其中，-C（-O）-Z-表示-C（-O）-CH 2 - ， - C（ - -C（= O）-NH-， - C（-O）-O - ， - C（-O） - S - ， - C（-O）-CH 2 CH 2 - ， - C（-O）-CH-CH - ， - C（-O）-CH O - ， - C（-O）-CH 2 S - ， - C（-O）-CH 2 CH 2 2-CH 2 - 或-C（ - ）-NR 8 CH 2 - ; R 1 - SUP>表示氢原子，取代或未取代的低级烷基等; R 2表示氢原子或羟基; R 3表示氢原子，取代或未取代的低级烷基等; R 5表示氢原子，羟基等; R 6表示氢原子，羟基，取代或未取代的低级烷基，或 R 7表示氢原子，卤素，取代或未取代的低级烷基等; n和k各自独立地表示0〜2的整数;＆lt; U STYLE = “ SINGLE“> ----表示单键，或与R 4连接的双键，其中如果是单键，则R” 对于N-甲基-D-葡萄糖酸的谷氨酸受体（NR2B / NMDA受体）具有拮抗作用的氨基酸或其药学上可接受的盐等）提供了含有NR2B亚基的天冬氨酸（NMDA）型。

5. 发明授权

US5478840A Tricyclic compounds 失效
标题翻译：三环化合物
公开(公告)号：US5478840A
公开(公告)日：1995-12-26
申请号：US294978
申请日：1994-08-24
申请人： Etsuo Ohshima , Fumihiko Kanai , Hideyuki Sato , Hiroyuki Obase , Toshiaki Kumazawa , Shiho Takahara , Tetsuji Ohno , Tomoko Ishikawa , Koji Yamada
发明人： Etsuo Ohshima , Fumihiko Kanai , Hideyuki Sato , Hiroyuki Obase , Toshiaki Kumazawa , Shiho Takahara , Tetsuji Ohno , Tomoko Ishikawa , Koji Yamada
IPC分类号： C07D403/06 , C07D403/12 , C07D403/14 , C07D405/06 , C07D471/04 , C07D521/00 , A61K31/44
CPC分类号： C07D249/08 , C07D231/12 , C07D233/56 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/06 , C07D471/04
摘要： A tricyclic compound represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, halogen or lower alkyl; A represents cyano, carboxyl, tetrazolyl, cyano-substituted phenyl, carboxyl-substituted phenyl or tetrazolyl-substituted phenyl; V represents --(CH.sub.2).sub.m --(wherein m is an integer of 0 to 2); W represents ##STR2## (wherein R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen, halogen, lower alkyl, cycloalkyl, halogenated lower alkyl, hydroxy, lower alkoxy, amino, lower alkylamino, carboxyl or lower alkoxycarbonyl; and Q.sup.1 --Q.sup.2 --Q.sup.3 --Q.sup.4 represents N.dbd.CH--CH.dbd.CH; X.sup.1 --X.sup.2 --X.sup.3 represents CH.dbd.CH--CH.dbd.CH, S--CH.dbd.CH or CH.dbd.CH--S; Y represents a single bond, CH.sub.2, O, S, CH.sub.2 O, OCH.sub.2, CH.sub.2 S, SCH.sub.2, CH.sub.2 CH.sub.2 or CH.dbd.CH; and Z.sup.1 --Z.sup.2 represents C.dbd.CH, CH--CH.sub.2 or CH--CH(COOH)-- or a pharmaceutically acceptable salt thereof. The compound of the present invention exhibits antagonism to angiotensin II receptors.
摘要翻译：由下式（I）表示的三环化合物：其中R 1表示氢，卤素或低级烷基; A代表氰基，羧基，四唑基，氰基取代的苯基，羧基取代的苯基或四唑基取代的苯基; V表示 - （CH 2）m - （其中m为0〜2的整数）; W表示（其中R2，R3和R4独立地表示氢，卤素，低级烷基，环烷基，卤代低级烷基，羟基，低级烷氧基，氨基，低级烷基氨基，羧基或低级烷氧基羰基;以及Q1-Q2-Q3-Q4 表示N = CH-CH = CH; X 1 -X 2 -X 3表示CH = CH-CH = CH，S-CH = CH或CH = CH-S; Y表示单键，CH 2，O，S，CH 2 O，OCH 2 ，CH2S，SCH2，CH2CH2或CH = CH; Z1-Z2表示C = CH，CH-CH2或CH-CH（COOH） - 或其药学上可接受的盐。本发明化合物显示对血管紧张素II受体的拮抗作用。

6. 发明授权

US5607955A Tricyclic compounds on angiotensin II receptor antagonists 失效
标题翻译：三环化合物作为血管紧张素II受体拮抗剂
公开(公告)号：US5607955A
公开(公告)日：1997-03-04
申请号：US431425
申请日：1995-05-01
申请人： Etsuo Ohshima , Fumihiko Kanai , Hideyuki Sato , Hiroyuki Obase , Toshiaki Kumazawa , Shiho Takahara , Tetsuji Ohno , Tomoko Ishikawa , Koji Yamada
发明人： Etsuo Ohshima , Fumihiko Kanai , Hideyuki Sato , Hiroyuki Obase , Toshiaki Kumazawa , Shiho Takahara , Tetsuji Ohno , Tomoko Ishikawa , Koji Yamada
IPC分类号： C07D403/06 , C07D403/12 , C07D403/14 , C07D405/06 , C07D471/04 , C07D521/00 , A61K31/41 , A61K31/415 , C07D233/54 , C07D235/04 , C07D257/04
CPC分类号： C07D249/08 , C07D231/12 , C07D233/56 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/06 , C07D471/04
摘要： A tricyclic compound represented by the following formula (I): ##STR1## exhibits antagonism to angiotensin II receptors.
摘要翻译：由下式（I）表示的三环化合物：显示对血管紧张素II受体的拮抗作用。

7. 发明授权

US5378701A Tricyclic compounds 失效
标题翻译：三环化合物
公开(公告)号：US5378701A
公开(公告)日：1995-01-03
申请号：US65916
申请日：1993-05-25
申请人： Etsuo Ohshima , Fumihiko Kanai , Hideyuki Sato , Hiroyuki Obase , Toshiaki Kumazawa , Shiho Takahara , Tetsuji Ohno , Tomoko Ishikawa , Koji Yamada
发明人： Etsuo Ohshima , Fumihiko Kanai , Hideyuki Sato , Hiroyuki Obase , Toshiaki Kumazawa , Shiho Takahara , Tetsuji Ohno , Tomoko Ishikawa , Koji Yamada
IPC分类号： C07D403/06 , C07D403/12 , C07D403/14 , C07D405/06 , C07D471/04 , C07D521/00 , A61K31/55 , C07D223/16 , C07D223/22
CPC分类号： C07D249/08 , C07D231/12 , C07D233/56 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/06 , C07D471/04
摘要： A tricyclic compound represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, halogen or lower alkyl; A represents cyano, carboxyl, tetrazolyl, cyano-substituted phenyl, carboxyl-substituted phenyl or tetrazolyl-substituted phenyl; V represents --(CH.sub.2).sub.m -- wherein m is an integer of 0 to 2; W represents ##STR2## and Q.sup.1 --Q.sup.2 --Q.sup.3 --Q.sup.4 represents N.dbd.CH--CH.dbd.CH, CH.dbd.CH--CH.dbd.CH or CH.sub.2 --CH.sub.2 --CH.sub.2 --CH.sub.2, ##STR3## and Q represents N or CH; X.sup.1 --X.sup.2 --X.sup.3 represents CH.dbd.CH--CH.dbd.CH, S--CH.dbd.CH or CH.dbd.CH--S; Y represents CH.sub.2 CH.sub.2 ; and Z.sup.1 --Z.sup.2 represents N--(CH.sub.2).sub.n -- wherein n is an integer of 1 to 3 or a pharmaceutically acceptable salt thereof.
摘要翻译：由下式（I）表示的三环化合物：其中R 1表示氢，卤素或低级烷基; A代表氰基，羧基，四唑基，氰基取代的苯基，羧基取代的苯基或四唑基取代的苯基; V表示 - （CH 2）m - ，其中m是0至2的整数; W表示，Q1-Q2-Q3-Q4表示N = CH-CH = CH，CH = CH-CH = CH或CH2-CH2-CH2-CH2， N或CH; X1-X2-X3表示CH = CH-CH = CH，S-CH = CH或CH = CH-S; Y表示CH 2 CH 2; Z1-Z2表示N-（CH2）n-，其中n为1〜3的整数或其药学上可接受的盐。

8. 发明授权

US09249135B2 Therapeutic agent for mood disorders 有权
标题翻译：情绪障碍治疗剂
公开(公告)号：US09249135B2
公开(公告)日：2016-02-02
申请号：US13393035
申请日：2010-09-02
申请人： Koji Yamada , Tomoyuki Kanda
发明人： Koji Yamada , Tomoyuki Kanda
IPC分类号： A61K31/34 , A61K31/35 , A61K31/426 , A61K31/435 , C07D417/14 , A61K31/4439 , A61K31/506 , A61K31/5377 , C07D491/048 , C07D491/052 , C07D495/04
CPC分类号： C07D417/14 , A61K31/34 , A61K31/35 , A61K31/426 , A61K31/435 , A61K31/4439 , A61K31/506 , A61K31/5377 , C07D491/048 , C07D491/052 , C07D495/04
摘要： Provided are an agent for the treatment and/or prophylaxis of a mood disorder comprising, as an active ingredient, a thiazole derivative represented by the formula (I) wherein R1 represents aryl or the like, and R2 represents pyridyl or the like, or a pharmaceutically acceptable salt thereof, and the like.
摘要翻译：提供了用于治疗和/或预防情绪障碍的药剂，其包含作为活性成分的由式（I）表示的噻唑衍生物，其中R 1表示芳基等，R 2表示吡啶基等，或药学上可接受的盐等。

9. 发明授权

US08945791B2 Oxygen side electrode for a fuel cell 有权
标题翻译：燃料电池用氧侧电极
公开(公告)号：US08945791B2
公开(公告)日：2015-02-03
申请号：US13636606
申请日：2011-03-23
申请人： Koichiro Asazawa , Koji Yamada , Hirohisa Tanaka , Kazuya Yamamoto , Tim Olson , Svitlana Pylypenko , Plamen Atanassov
发明人： Koichiro Asazawa , Koji Yamada , Hirohisa Tanaka , Kazuya Yamamoto , Tim Olson , Svitlana Pylypenko , Plamen Atanassov
IPC分类号： H01M8/10 , H01M4/90 , H01M4/88 , H01M4/86
CPC分类号： H01M4/8605 , H01M4/8828 , H01M4/9008 , H01M4/9083 , H01M8/1011 , H01M2004/8689 , H01M2250/20 , Y02E60/523 , Y02T90/32
摘要： In a fuel cell including an electrolyte layer allowing an anion component to migrate, and a fuel-side electrode and an oxygen-side electrode arranged to face each other while sandwiching the electrolyte layer, the oxygen-side electrode contains a first catalyst containing a first transition metal and polypyrrole, and a second catalyst containing a second transition metal and a porphyrin ring-containing compound so that the mixing ratio of the first catalyst relative to 100 parts by mass of the total amount of the first catalyst and the second catalyst is more than 10 parts by mass, and below 90 parts by mass.
摘要翻译：在包含允许阴离子成分迁移的电解质层的燃料电池中，并且在夹着电解质层的同时配置为彼此面对的燃料侧电极和氧气侧电极，所述氧气侧电极含有含有第一催化剂的第一催化剂，过渡金属和聚吡咯，以及含有第二过渡金属和含卟啉环的化合物的第二催化剂，使得第一催化剂与第一催化剂和第二催化剂的总量相对于100质量份的混合比更多 10质量份以下，90质量份以下。

10. 发明授权

US08815469B2 Electrolyte, and fuel cell, Li secondary battery, secondary battery and primary battery using the electrolyte 有权
标题翻译：电解液，燃料电池，锂二次电池，二次电池和一次电池使用电解液
公开(公告)号：US08815469B2
公开(公告)日：2014-08-26
申请号：US13189994
申请日：2011-07-25
申请人： Akihiro Shinohara , Naoki Hasegawa , Koji Yamada , Susumu Yamaguchi
发明人： Akihiro Shinohara , Naoki Hasegawa , Koji Yamada , Susumu Yamaguchi
IPC分类号： H01M8/08 , H01M10/0567 , H01M8/10 , H01M6/16 , H01M12/06 , H01M10/0568
CPC分类号： H01M10/0567 , H01M6/166 , H01M6/168 , H01M8/1016 , H01M10/0568 , H01M12/06 , Y02E60/128 , Y02E60/521
摘要： Provided is an electrolyte equipped with a hydrophilic portion having a cyclic quaternary ammonium salt and a hydrophobic portion bonded to the hydrophilic portion; and a fuel cell, a Li secondary battery, secondary battery and a primary battery using the electrolyte. The electrolyte has preferably a structure represented by the formula (A) or (B), wherein P′ represents a hydrophobic portion, R1 and R2 each represents hydrogen, fluorine, a hydroxy group, or a hydrocarbon or fluorinated hydrocarbon group having from 1 to 10 carbon atoms, R3 and R4 each represents a hydrocarbon, fluorinated hydrocarbon, or a fluorocarbon group having from 1 to 10 carbon atoms, r and s each represents an integer of 0 or greater but not greater than 8 and satisfies 1≦r+s≦8, u represents an integer and satisfies 2≦u≦9, and X− represents a counter anion.
摘要翻译：本发明提供一种电解质，其配备有具有环状季铵盐的亲水部分和与该亲水部分结合的疏水部分; 以及燃料电池，Li二次电池，二次电池和使用电解质的一次电池。电解质优选具有由式（A）或（B）表示的结构，其中P'表示疏水部分，R1和R2各自表示氢，氟，羟基或烃或氟化烃基，其具有1〜 10个碳原子，R 3和R 4各自表示烃，氟化烃或具有1至10个碳原子的氟碳基团，r和s各自表示0或更大但不大于8的整数，并且满足1＆nlE; r + s＆nlE ; 8，u表示整数，满足2＆nlE; u＆nlE; 9，X表示抗衡阴离子。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式